FTSE 100 news / Companies and sectors / GSK / GSK acquires cancer rights for $750m

GSK acquires cancer rights for $750m

+6.7 strongly positive

GSK agreed a $750m deal for ChImagen's myeloma T-cell engager.

8 headlines from 3 outlets, from 4 October 2026 to 10 October 2026. The story's tone is the average of its headlines' own scores.

How each outlet covered it

Average tone of each outlet's headlines in this story. One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Outlet	Headlines	Tone
AD HOC NEWS	4	+6.6
Kalkine Media	3	+6.8
foreignpolicyjournal.com	1	+6.7

Day by day

Saturday 10 October 2026 2 headlines

Coverage of GSK's $750m cancer rights deal, with Goldman keeping its target.

+6.7 GSK secures USD 750 million cancer rights. Goldman keeps GBp 1,860 target for GSK stock AD HOC NEWS
Secures cancer rights; Goldman keeps target.
+6.3 GSK (LSE:GSK) Back In Focus: Does The Nuvalent Agreement Strengthen Its Cancer Pipeline Today? Kalkine Media
Nuvalent agreement may strengthen cancer pipeline.

Friday 9 October 2026 1 headline

Kalkine asks whether the T cell engager acquisition strengthens GSK's blood-cancer pipeline.

+6.7 Can GSK plc (LSE:GSK) strengthen its blood-cancer pipeline after this week's T cell engager acquisition? Kalkine Media
T cell engager acquisition strengthens blood-cancer pipeline

Thursday 8 October 2026 1 headline

A piece asks why GSK took global rights to a Chimagen myeloma drug.

+7.5 Why Has FTSE 100 GSK (LSE:GSK) Taken Global Rights to a Chimagen Myeloma Drug? Kalkine Media
Takes global rights to a Chimagen myeloma drug.

Wednesday 7 October 2026 1 headline

GSK announced a potential USD 750 million multiple myeloma deal.

+5.7 GSK stock: company announces potential USD 750 million multiple myeloma deal AD HOC NEWS
Potential USD 750m multiple myeloma deal signals pipeline expansion

Monday 5 October 2026 2 headlines

GSK agreed a $750m deal for ChImagen's myeloma T-cell engager.

+7.0 GSK agrees to acquire myeloma therapy. GSK stock costs EUR 20.83 AD HOC NEWS
GSK acquiring a myeloma therapy expands its oncology pipeline.
+6.7 GSK (NYSE: GSK) Strikes $750 Million Deal To Acquire Trispecific T-Cell Engager From ChImagen Biosciences For Multiple Myeloma foreignpolicyjournal.com
$750 million deal adds a multiple myeloma T-cell engager.

Sunday 4 October 2026 1 headline

GSK agrees to acquire a ChImagen therapy for $750m.

+7.0 GSK agrees to acquire ChImagen therapy: what it means for GSK stock at $750 million AD HOC NEWS
GSK acquiring ChImagen therapy for $750 million, pipeline expansion.

GSK: all news analysis · Sector · FTSE 100 news